Who
Ronald C. Renaud Jr.
Director
Company insider
Files Form 4 as: CEO & President, Kailera Therapeutics; Director, Upstream Bio; President & CEO, Cerevel Therapeutics Holdings; Director, Atara Biotherapeutics; Director, ImageneBio; Chief Executive Officer, Translate Bio; Director, Chimerix; Director, Akebia Therapeutics.
In numbers
- Trades disclosed
- 103
- Buys
- 3
- Sells
- 1
- Bought
- $2.1M
- Sold
- $36.3M
- Companies
- 11
- Companies where not an officer
- 6
- First trade
- 31 Dec 2006
- Last trade
- 9 Jun 2026
- Last filed
- 11 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Jun 2026filed 11 Jun 2026 | KLRA Kailera TherapeuticsBiotechnology | SEC FORM 4 Code M | $200K38,094 at $5.25 | filing |
| 9 Jun 2026filed 11 Jun 2026 | KLRA Kailera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —38,094 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | KLRA Kailera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —38,094 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | KLRA Kailera TherapeuticsBiotechnology | SEC FORM 4 Code M | $200K38,094 at $5.25 | filing |
| 9 Jun 2026filed 11 Jun 2026 | UPB Upstream Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —17,096 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | UPB Upstream Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —17,096 at $0.00 | filing |
| 16 Apr 2026filed 20 Apr 2026 | KLRA Kailera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 16 Apr 2026filed 20 Apr 2026 | KLRA Kailera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 16 Apr 2026filed 20 Apr 2026 | KLRA Kailera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 16 Apr 2026filed 20 Apr 2026 | KLRA Kailera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 10 Jun 2025filed 12 Jun 2025 | UPB Upstream Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —17,096 at $0.00 | filing |
| 10 Oct 2024filed 15 Oct 2024 | UPB Upstream Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —17,096 at $0.00 | filing |
| 1 Aug 2024filed 5 Aug 2024 | Cerevel Therapeutics Holdingsoption or derivative | SEC FORM 4 Code D | —215,749 | filing |
| 1 Aug 2024filed 5 Aug 2024 | Cerevel Therapeutics Holdingsoption or derivative | SEC FORM 4 Code D | —284,023 at $0.00 | filing |
| 1 Aug 2024filed 5 Aug 2024 | Cerevel Therapeutics Holdingsoption or derivative | SEC FORM 4 Code D | —320,742 at $0.00 | filing |
| 1 Aug 2024filed 5 Aug 2024 | Cerevel Therapeutics Holdings | SEC FORM 4 Code D | —160,452 | filing |
| 1 Aug 2024filed 5 Aug 2024 | Cerevel Therapeutics Holdings | SEC FORM 4 Code D | —83,857 | filing |
| 19 Jan 2024filed 23 Jan 2024 | Cerevel Therapeutics Holdingsoption or derivative | SEC FORM 4 Code A | —284,023 at $0.00 | filing |
| 19 Dec 2023filed 21 Dec 2023 | Cerevel Therapeutics Holdingsoption or derivative | SEC FORM 4 Code M | —160,452 at $0.00 | filing |
| 19 Dec 2023filed 21 Dec 2023 | Cerevel Therapeutics Holdings | SEC FORM 4 Code M | —160,452 | filing |
News
Analyzing Akebia Therapeutics (NASDAQ:AKBA) and Pharming Group (NASDAQ:PHAR)AKBA · tickerreport.com · 18 Oct 2026
0 headlines in the last 90 days name Ronald C. Renaud Jr.; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.